Literature DB >> 12692106

Complementary medicine use among women enrolled in a genetic testing program.

Lisa M DiGianni1, Haesook T Kim, Karen Emmons, Rebecca Gelman, Kathy J Kalkbrenner, Judy E Garber.   

Abstract

The purpose of this study is to explore complementary and alternative medicine (CAM) use and factors influencing CAM use by women enrolled in a genetic testing program for predisposition to breast/ovarian cancer. A cohort of 236 high-risk women completed baseline questionnaires at enrollment into BRCA1/2 testing program. CAM use and correlates of use were assessed using logistic regression models. CAM was used by 53% of the overall cohort. Cancer survivors reported significantly more use of complementary treatments than did unaffected women (61 versus 42%; P < 0.05). Participants had good overall health behaviors; daily fruit/vegetable consumption was significantly related to CAM use. Increased depression level, knowledge of cancer genetics, and frequency of breast self-examination were significantly associated with using CAM for cancer survivors. Among unaffected women only, cancer risk perception and sunscreen use were significantly correlated with CAM use. Recognition of heightened breast cancer risk is correlated with increased complementary therapy use by unaffected women undergoing genetic testing for cancer predisposition but not to the extent that cancer survivors use these strategies. Any potential effects of the genetic information itself on CAM use, and any possible relationship of CAM use to other risk reduction behaviors, require further research.

Entities:  

Mesh:

Year:  2003        PMID: 12692106

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  8 in total

1.  Attitudes toward childbearing and prenatal testing in individuals undergoing genetic testing for Lynch syndrome.

Authors:  Akriti Dewanwala; Anu Chittenden; Margery Rosenblatt; Rowena Mercado; Judy E Garber; Sapna Syngal; Elena M Stoffel
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

2.  High use of complementary and alternative medicine among a large cohort of women with a family history of breast cancer: the Sister Study.

Authors:  Heather Greenlee; Christine L Sardo Molmenti; Laura Falci; Ross Ulmer; Sandra Deming-Halverson; Lisa A DeRoo; Dale P Sandler
Journal:  Breast Cancer Res Treat       Date:  2016-03-26       Impact factor: 4.872

3.  Linking genetic counseling content to short-term outcomes in individuals at elevated breast cancer risk.

Authors:  Kimberly M Kelly; Lee Ellington; Nancy Schoenberg; Parul Agarwal; Thomas Jackson; Stephanie Dickinson; Jame Abraham; Electra D Paskett; Howard Leventhal; Michael Andrykowski
Journal:  J Genet Couns       Date:  2014-03-28       Impact factor: 2.537

4.  Diet and predictors of dietary intakes in women with family history of breast and/or ovarian cancer.

Authors:  Archana J McEligot; Michele Mouttapa; Argyrios Ziogas; Hoda Anton-Culver
Journal:  Cancer Epidemiol       Date:  2009-10-14       Impact factor: 2.984

5.  Familial and perceived risk of breast cancer in relation to use of complementary medicine.

Authors:  Cynthia D Myers; Paul B Jacobsen; Yifan Huang; Marlene H Frost; Christi A Patten; James R Cerhan; Thomas A Sellers
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-06-09       Impact factor: 4.254

6.  Use of Chinese medicine by cancer patients: a review of surveys.

Authors:  Bridget Carmady; Caroline A Smith
Journal:  Chin Med       Date:  2011-06-09       Impact factor: 5.455

7.  The Relationship between Complementary and Alternative Medicine Use and Breast Cancer Early Detection: A Critical Review.

Authors:  Laura C Dale; Carolyn C Gotay
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-19       Impact factor: 2.629

8.  Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer.

Authors:  Christine M Mueller; Phuong L Mai; Jaime Bucher; June A Peters; Jennifer T Loud; Mark H Greene
Journal:  BMC Complement Altern Med       Date:  2008-04-30       Impact factor: 3.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.